Clinical trials: CNS
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease, Cognitive Decline
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 ([18F]AV-1451).
- Trial name
- NCT04080544
- Testing
- [18F]AV-1451, Positron Emission Tomography
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Neil M Rofsky, MD, MHA
Migraine
Ginger Capsules for the Acute Treatment of Migraine Attacks
The main objective of the study was to evaluate ginger efficacy as an adjuvant to ketoprofen for the treatment of headache and other symptoms related with migraine attacks.
- Trial name
- NCT02568644
- Testing
- Extract of ginger, Cellulose, Intravenous ketoprofen
- Volunteers
- 60 people
- Sponsor
- Federal University of Minas Gerais
B-cell Lymphomas
High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
This prospective trial will assess the activity and feasibility of a new high-dose methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell lymphomas and CNS involvement at diagnosis or relapse.
- Trial name
- SCNSL1 (NCT00801216)
- Testing
- High-dose sequential chemotherapy and autologous transplant
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Andrés José Maria Ferreri
Multiple Sclerosis, Fatigue
Aspirin for Treatment of Multiple Sclerosis-Related Fatigue
The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).
- Trial name
- NCT00467584
- Testing
- High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mayo Clinic
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Dementia of Alzheimer Type
Stimulation to Improve Memory
This study will test the effects of different doses of a form of non-invasive brain stimulation for the treatment of individuals with mild cognitive impairment (MCI) and dementia of the Alzheimer's Type (DAT).
- Trial name
- STIM (NCT03875326)
- Testing
- 1 mA HD-tDCS, 2 mA HD-tDCS, 3 mA HD-tDCS
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- University of Michigan
Cirrhosis, Hepatic Encephalopathy
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
- Trial name
- NCT04899115
- Testing
- VE303, oral vancomycin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patricia Bloom
Wilson Disease
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.
- Trial name
- NCT02763215
- Testing
- Standard of Care Medications
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 64 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cardiovascular Disease, Peripheral Arterial Disease
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death…
- Conditions
- Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
- Trial name
- HPS2-THRIVE (NCT00461630)
- Testing
- ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin
- Where
- United Kingdom
- Volunteers
- 25,673 people
- Sponsor
- University of Oxford
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Traumatic Brain Injury, Multiple Sclerosis
Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging
This study will test a new MRI sequence that measures cerebral blood flow (CBF). Because this technique for measuring CBF is new, there is little information on what the normal values for different regions of the brain should be.
- Conditions
- Traumatic Brain Injury, Multiple Sclerosis, Alzheimer's Disease, Tumor
- Trial name
- NCT02767609
- Testing
- Magnetic Resonance Imaging
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Multiple System Atrophy
Safinamide for Multiple System Atrophy (MSA)
The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner.
- Trial name
- NCT03753763
- Testing
- Safinamide Methanesulfonate
- Where
- 19 sites in Italy, Spain
- Volunteers
- 49 people
- Sponsor
- Zambon SpA
Spinal Cord Injuries
A Randomised, Cross-over, Open-labelled Test Catheter Acceptance Study
The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.
- Trial name
- NCT00990093
- Testing
- test intermittent catheter, Intermittent catheterization
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Coloplast A/S
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Sphingomyelin Lipidosis
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa.
- Trial name
- NCT02004704
- Testing
- GZ402665
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Tourette's Syndrome
Ecopipam Treatment of Tourette Syndrome
Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate.
- Trial name
- NCT01244633
- Testing
- Ecopipam
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Psyadon Pharma
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.